Golimumab

Category: biologic

Aliases: Simponi, Simponi Aria, anti-TNFα mAb

Pharmacological Mechanism

Fully human IgG1κ mAb generated by transgenic mouse platform, binds both soluble and transmembrane TNFα. Monthly SC dosing improves adherence vs adalimumab q2w. Once-monthly cadence makes golimumab attractive for patients with stable disease.

Half-Life (t½)

SC: 288h, IV: 288h

Dosing Guidelines

Target Organ Systems